<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04226248</url>
  </required_header>
  <id_info>
    <org_study_id>Study 2018-2030</org_study_id>
    <nct_id>NCT04226248</nct_id>
  </id_info>
  <brief_title>CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)</brief_title>
  <acronym>CHIEF PD</acronym>
  <official_title>CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease: A Phase 3 Randomised, Double-blind Placebo-controlled Trial of Rivastigmine to Prevent Falls in Parkinson's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bristol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal United Hospitals Bath NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bristol</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson's disease is a common condition particularly affecting older people. Falls are a&#xD;
      very frequent complication of the disease affecting 60% of people with Parkinson's every&#xD;
      year. As the population ages, the number of people living with Parkinson's disease and the&#xD;
      occurrence of complications will increase. The loss of the chemical dopamine in the brain&#xD;
      causes walking in Parkinson's to become slower, unsteady and irregular. People with the&#xD;
      condition are therefore at a very high risk of falling. To some extent, people can compensate&#xD;
      for these changes by paying more attention to their walking. However, Parkinson's also&#xD;
      diminishes memory and thinking ability. This decreases people's ability to pay attention to&#xD;
      their walking, especially when doing something at the same time.&#xD;
&#xD;
      Cholinesterase inhibitor (ChEis) are drugs that are currently used to treat people with&#xD;
      memory problems in Parkinson's. The effect of these drugs on falls in Parkinson's has been&#xD;
      tested to show that treatment has the potential to almost halve the number of falls.&#xD;
&#xD;
      This trial aims to definitively determine whether cholinesterase inhibitors (ChEi), can&#xD;
      prevent falls in Parkinson's and whether this treatment is cost effective. 600 participants&#xD;
      with Parkinson's disease will be enrolled from hospitals throughout the UK. Participants will&#xD;
      be randomly assigned to either receive the drug (ChEi) via a patch or receive a placebo&#xD;
      (dummy) treatment via a patch.&#xD;
&#xD;
      Neither the researchers nor the participants will know which group they are in. Participants&#xD;
      will take the medication for 12 months and record any falls that they experience in diaries.&#xD;
      If successful, this treatment in Parkinson's disease, would tackle one of the most disabling&#xD;
      complications of the disease and positive findings will provide robust evidence to change&#xD;
      clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Phase III Randomised Controlled Trial of Rivastigmine versus Placebo</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fall rate</measure>
    <time_frame>12 months from the day the IMP is commenced</time_frame>
    <description>Fall rate measured using monthly diaries and telephone calls prospectively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease (PD)</measure>
    <time_frame>12 months</time_frame>
    <description>MDS-UPDRS total score in the practically defined 'ON' state and each individual subscale (1-4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freezing of gait</measure>
    <time_frame>12 months</time_frame>
    <description>New Freezing of Gait Questionnaire (NFOGQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frailty</measure>
    <time_frame>12 months</time_frame>
    <description>Frailty assessed by the SHARE-FI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical performance</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by the Short physical performance battery (SPPB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freezing of Gait Assessment</measure>
    <time_frame>12 months</time_frame>
    <description>Gait speed measured with Freezing of Gait (turn test)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait Assessment</measure>
    <time_frame>12 months</time_frame>
    <description>Gait speed measured with and without dual task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition</measure>
    <time_frame>12 months</time_frame>
    <description>Montreal Cognitive Assessment (MoCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>12 months</time_frame>
    <description>Geriatric Depression Scale (GDS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fear of falling</measure>
    <time_frame>12 months</time_frame>
    <description>Iconographical Fall Efficacy Scale (ICON-FES)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysphagia</measure>
    <time_frame>12 months</time_frame>
    <description>Swallowing Disturbance Questionnaire (SDQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant health related quality of life</measure>
    <time_frame>0,1,3,6 9 and 12 months</time_frame>
    <description>EuroQoL 5D-5L health status questionnaire (EQ-5D-5L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Capability of older people</measure>
    <time_frame>12 months</time_frame>
    <description>ICEpop CAPability measure for Older people (ICECAP-O)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (all cause and PD-related)</measure>
    <time_frame>12 months</time_frame>
    <description>Office of National Statistics (ONS) data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness by NHS resource use</measure>
    <time_frame>12 months</time_frame>
    <description>NHS Hospital Episode Statistics (HES) data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apathy</measure>
    <time_frame>12 months</time_frame>
    <description>Starkstein Apathy Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Active (Rivastigmine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rivastigmine Transdermal Patches</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Matched Transdermal Patches</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine Transdermal System</intervention_name>
    <description>Rivastigmine Trandermal Patches applied once a day for up to 12 months</description>
    <arm_group_label>Active (Rivastigmine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Transdermal System</intervention_name>
    <description>Placebo Trandermal Patches applied once a day for up to 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of idiopathic Parkinson's disease.&#xD;
&#xD;
          -  Modified Hoehn and Yahr stage 1-4 disease as determined at baseline visit.&#xD;
&#xD;
          -  Have experienced a fall in the previous year.&#xD;
&#xD;
          -  Able to walk ≥10m without aids or assistance.&#xD;
&#xD;
          -  18+ years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous ChEi use in 12 months prior to enrolment.&#xD;
&#xD;
          -  Hypersensitivity to rivastigmine&#xD;
&#xD;
          -  Dementia diagnosed according to MDS criteria (6).&#xD;
&#xD;
          -  Inability to attend or comply with treatment or follow-up scheduling.&#xD;
&#xD;
          -  Non-English-speaking patients (cognitive tests performed in English).&#xD;
&#xD;
          -  Falling ≥4x per day.&#xD;
&#xD;
          -  Unwillingness to use an acceptable method of contraception for the duration of the&#xD;
             trial if they are of childbearing potential.&#xD;
&#xD;
          -  Pregnancy and/or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Henderson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bristol</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Neumann, PhD</last_name>
    <phone>04401174283111</phone>
    <phone_ext>83111</phone_ext>
    <email>chief-pd@bristol.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alison Bamford</last_name>
    <phone>004401172483113</phone>
    <phone_ext>83113</phone_ext>
    <email>chief-pd@bristol.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barking, Havering and Redbridge University Hospitals NHS trust</name>
      <address>
        <city>Romford</city>
        <state>Accepted</state>
        <zip>BS8 1NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyn Liddiard</last_name>
      <phone>01174283113</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Anjum Misbadhuddin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alagaratnam Niruban</last_name>
      <phone>01603 288177</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Alagaratnam Niruban</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal United Hospitals Bath NHS Foundation Trust</name>
      <address>
        <city>Bath</city>
        <state>Somerset</state>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Hamlin</last_name>
      <phone>01225 825797</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Veronica Lyell</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Barnsley Hospital NHS Foundation Trust</name>
      <address>
        <city>Barnsley</city>
        <zip>S75 2EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Sanderson</last_name>
      <phone>01226 435084</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Bahaa Madi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Dorset NHS Foundation Trust</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH23 2JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rochelle Hernandez</last_name>
      <phone>0300 019 5136</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Emma Gunter</last_name>
      <phone>0300 019 5284</phone>
    </contact_backup>
    <investigator>
      <last_name>Divya Tiwali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess of Wales Hospital (Cwm Taf Morgannwg University Health Board)</name>
      <address>
        <city>Bridgend</city>
        <zip>CF31 1RQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Jones</last_name>
      <phone>01656 752477</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Sandip Raha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Bristol NHS Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Watkins</last_name>
      <phone>0117 4148276</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Edward Richfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan Whone</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pennine Acute Hospitals NHS Trust</name>
      <address>
        <city>Bury</city>
        <zip>BL9 7TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosan Joseph</last_name>
      <phone>0161 778 2634</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Sanniah Hussain</last_name>
      <phone>0161 778 2559</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Raw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Derby and Burton NHS Foundation Trust</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Hayman</last_name>
      <phone>07387248757</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Rob Skelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gateshead Health NHS Foundation Trust</name>
      <address>
        <city>Gateshead</city>
        <zip>NE9 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryony Storey</last_name>
      <phone>01914456317</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Claire McDonald</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Hospitals NHS Foundation Trust</name>
      <address>
        <city>Gloucester</city>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Bullock</last_name>
      <phone>0300 4225478</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Sangeeta Kulkarni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 3AX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prisca Mpofu</last_name>
      <phone>01133925073</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Stephen Butterworth</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremy Cosgrove</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Foundation Trust</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Hailstone</last_name>
      <phone>01162586772</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Kate O'Kelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Walton Centre NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Illingworth</last_name>
      <phone>0151 556 3963</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Michael Bonello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Homerton University Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>E9 6SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Holbrook</last_name>
      <phone>02085107412</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Ashwani Jha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Lopes</last_name>
      <phone>02033111714</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Sophie Molloy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelina Manoharan</last_name>
      <phone>2034488608</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Tabish Saifee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northumbria Healthcare NHS Foundation Trust</name>
      <address>
        <city>Newcastle</city>
        <zip>NE27 0QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Tanney</last_name>
      <phone>0191 2934087</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>James Fisher</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Walker</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Whitestone</last_name>
      <phone>01865 234309</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Sanja Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Plymouth NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 5FP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Dobranszky-oroian</last_name>
      <phone>01752 437 485</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Camille Carroll</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>MA6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Whiston</last_name>
      <phone>01612060534</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Christopher Kobylecki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Somerset NHS Foundation Trust</name>
      <address>
        <city>Taunton</city>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Whitcher</last_name>
      <phone>01823 343635</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Anita Goff</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Campbell</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital</name>
      <address>
        <city>Yeovil</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Lewis</last_name>
      <phone>01935384854</phone>
      <email>chief-pd@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Rani Sophia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>Parkinson</keyword>
  <keyword>Rivastigmine</keyword>
  <keyword>Falls</keyword>
  <keyword>Cholinesterase Inhibitors</keyword>
  <keyword>Phase III</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivastigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

